Core Insights - Orion Corporation has secured an exclusive commercial license for a monoclonal antibody from Abzena, aimed at addressing a significant clinical need in oncology [1][2] - The antibody was developed using Abzena's proprietary Composite Human Antibody (CHAb™) technology, which emphasizes a comprehensive approach to selecting a lead candidate [2][3] - Abzena has over 20 years of experience in monoclonal antibody programs, with capabilities in both the UK and the US for development and manufacturing [3][4] Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a century of experience, focusing on human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients [5][7] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [5][7] - Orion's research and development primarily targets oncology and pain management, with proprietary products addressing various health conditions [5][7] Abzena Overview - Abzena is a leading end-to-end contract development and manufacturing organization (CDMO) specializing in bioconjugates and complex biologics [4] - The company offers integrated programs and services to streamline the development of new treatments, with facilities in San Diego, Bristol, and Cambridge [4] - Abzena is owned by Welsh, Carson, Anderson & Stowe, a prominent private equity investor [4]